Hexaminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non-Muscle-Invasive Bladder Cancer: Review of the Evidence and Recommendations

European Urology

Volumn 57, Issue 4, 2010, Pages 607-614

  Witjes, J Alfred ^a   Redorta, Juan Palou ^b   Jacqmin, Didier ^c   Sofras, Frank ^d   Malmström, Per Uno ^e   Riedl, Claus ^f   Jocham, Dieter ^g   Conti, Giario ^h   Montorsi, Francesco ⁱ   Arentsen, Harm C ^a   Zaak, Dirk ^j   Mostafid, A Hugh ^k   Babjuk, Marko ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITY OF CRETE   (Greece)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f Landesklinikum Thermenregion Baden ^*  (Austria)

^g UNIVERSITY OF LÜBECK   (Germany)

^h SANT ANNA HOSPITAL   (Italy)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j UNIVERSITY OF MUNICH   (Germany)

^k NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

more..

Author keywords

Carcinoma in situ; CIS detection; Hexaminolevulinate; Non muscle invasive bladder cancer; PDD; Photodynamic diagnosis; Recurrence

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

BLADDER CANCER; BLUE LIGHT; CANCER INVASION; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL PRACTICE; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; FLUORESCENCE IMAGING; FOLLOW UP; HUMAN; MEDLINE; PHOTODYNAMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT; WHITE LIGHT;

AMINOLEVULINIC ACID; CYSTECTOMY; CYSTOSCOPY; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 77549086469     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.01.025     Document Type: Review

References (49)

1. European Cancer Observatory. Cancer: bladder. International Agency for Research on Cancer Web site. http://eu-cancer.iarc.fr/cancer-20-bladder.html,en. Accessed October 2009.
2. Bladder cancer survival statistics. Cancer Research UK Web site. http://info.cancerresearchuk.org/cancerstats/types/bladder/#survival. Accessed April 2009.
3. Shah A., Rachet B., Mitry E., Cooper N., Brown C.M., and Coleman M.P. Survival from bladder cancer in England and Wales up to 2001. Br J Cancer 99 (2008) 86-89
4. Quinn MJ, Babb P, Brock A, Kirby L, Jones J. Cancer trends in England and Wales 1950-1999. Studies on medical and population subjects No. 66. London, United Kingdom: Office for National Statistics; 2001.
5. UK bladder cancer incidence statistics. Cancer Research UK Web site. http://info.cancerresearchuk.org/cancerstats/types/bladder/incidence/. Accessed June 2009.
6. Lee R., and Droller M.J. The natural history of bladder cancer. Implications for therapy. Urol Clin North Am 27 (2000) 1-13
7. Frampton J.E., and Plosker G.L. Hexylaminolevulinate in the detection of bladder cancer. Drugs 66 (2006) 571-578
8. Sanger V.K., Ragavan N., Matanhelia S.S., Watson M.W., and Blades R.A. The economic consequences of prostate and bladder cancer in the UK. BJU Int 95 (2005) 59-63
9. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
10. Brausi M., Collette L., Kurth K., et al. Variability in recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC trials. Eur Urol 41 (2002) 523-531
11. Denzinger S., Rössler W., and Otto W. Photodynamic diagnostic of superficial bladder carcinoma [in German]. Dtsch Med Wochenschr 132 (2007) 2332-2335
12. Witjes J.A. Bladder carcinoma in situ in 2003: state of the art. Eur Urol 45 (2004) 142-146
13. Holzbeierlein J.M., and Smith Jr. J.A. Surgical management of noninvasive bladder cancer (stages Ta/T1/CIS). Urol Clin North Am 27 (2000) 15-24
14. Witjes J.A., Kiemeney L.A.L.M., Verbeek A.L.M., and Heijbroek R.P. Debruyne FMJ; Dutch South East Cooperative Urological Group. Random bladder biopsies and the risk of recurrent superficial bladder cancer: a prospective study in 1026 patients. World J Urol 10 (1992) 231-234
15. van der Meijden A., Oosterlinck W., Brausi M., et al. Significance of bladder biopsies in Ta,T1 bladder tumors: a report from the EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 35 (1999) 267-271
16. May F., Treiber U., Hartung R., and Schwaibold H. Significance of random bladder biopsies in superficial bladder cancer. Eur Urol 44 (2003) 47-50
17. Schmidbauer J., Witjes F., Schmeller N., Donat R., Susani M., and Marberger M. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 171 (2004) 135-138
18. Grossman H.B., Gomella L., Fradet Y., et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 178 (2007) 62-67
19. Fradet Y., Grossman H.B., Gomella L., et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol 178 (2007) 68-73
20. Jocham D., Witjes F., Wagner S., et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol 174 (2005) 862-866
21. Jichlinski P., Guillou L., Karlsen S.J., et al. Hexylaminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer-a multicenter study. J Urol 170 (2003) 226-229
22. Riedl C.R., Daniltchenko D., Koenig F., Simak R., Loening S.A., and Pflueger H. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 165 (2001) 1121-1123
23. Kriegmair M., Zaak D., Rothenberger K.H., et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 168 (2002) 475-478
24. Filbeck T., Pichlmeier U., Knuechel R., Wieland W.F., and Roessler W. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 168 (2002) 67-71
25. Babjuk M., Soukup V., Petrik R., Jirsa M., and Dvoracek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int 96 (2005) 798-802
26. Daniltchenko D.I., Riedl C.R., Sachs M.D., et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol 174 (2005) 2129-2133
27. Denzinger S., Wieland W.F., Otto W., Filbeck T., Knuechel R., and Burger M. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study. BJU Int 101 (2007) 566-569
28. Denzinger S., Burger M., Walter B., et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology 69 (2007) 675-679
29. Zaak D., Wieland W.F., Stief C.G., and Burger M. Routine use of photodynamic diagnosis of bladder cancer: practical and economic issues. Eur Urol Suppl 7 (2008) 536-541
30. Burger M., Zaak D., Stief C.G., et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur Urol 52 (2007) 142-147
31. Stenzl A., Hoeltl L., and Bartsch G. Fluorescence assisted transurethral resection of bladder tumours: is it cost effective?. Eur Urol: 39 (2001) 31
32. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou J. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/TaT1_BC.pdf. Updated 2009. Accessed April 2009.
33. Babjuk M, Matouskova M, Finek J. Guidelines in oncourology. Praha, Czech Republic: Galen. In press.
34. Comité de Cancérologie de l'Association Française d'Urologie. Diagnostic et bilan d'extension des tumeurs urothéliales. Prog Urol 2007; 17:1066-9.
35. Stenzl A., Jocham D., and Jichlinski P. Photodynamic diagnosis in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology [in German]. Urologe 47 (2008) 982-987
36. Dutch Urological Association. Diagnosis, treatment and follow-up of urothelial carcinoma of the bladder. Utrecht, The Netherlands: Dutch Urological Association; August 2008.
37. British Association of Urological Surgeons/British Uro-oncology Group. MDT (multi-disciplinary team) guidance for managing bladder cancer. Peterborough and Stamford Hospitals Web site. http://www.echurology.co.uk/bausca/MDT%20Guidance%20for%20Bladder%20Canc er.pdf. Accessed August 2009.
38. Scottish Intercollegiate Guidelines Network (SIGN). Management of transitional cell carcinoma of the bladder (SIGN 85). Edinburgh, Scotland: SIGN; 2005.
39. Witjes J.A., and Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4 (2007) 542-549
40. Burger M., Stief C.G., Zaak D., et al. Hexaminolevulinate is equal to 5-aminolevulinic acid concerning residual tumor and recurrence rate following photodynamic diagnostic assisted transurethral resection of bladder tumors. Urology 74 (2009) 1282-1286
41. Stenzl AS, Poessler WR, Fradet YF, et al. Hexvix fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study [abstract]. Presented at: 24th Annual European Association of Urology Congress; March 17-21; Stockholm, Sweden; 2009.
42. Jichlinski P., and Jacqmin D. Photodynamic diagnosis in non-muscle-invasive bladder cancer. Eur Urol Suppl 7 (2008) 529-535
43. Mowatt G, N'Dow J, Zhu S, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy [abstract]. Presented at: 24th Annual European Association of Urology Congress; March 17-21; Stockholm, Sweden; 2009.
44. Witjes J.A., Moonen P.M.J., and van der Heijden A.G. Comparison of hexaminolevulinate based flexible and rigid fluorescence cystoscopy with rigid white light cystoscopy in bladder cancer: results of a prospective phase II study. Eur Urol 47 (2005) 319-322
45. Loidl W., Schmidbauer J., Susani M., and Marberger M. Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?. Eur Urol 47 (2005) 323-326
46. Draga R.O.P., Grimbergen M.C.M., Kok E.T., Jonges T.N., and van Swol C.F.P. Bosch JLHR. Photodynamic diagnosis (5-aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. Eur Urol 57 (2010) 655-660
47. Ray E.R., Chatterton K., Thomas K., Khan M.S., Chandra A., and O'Brien T.S. Hexylaminolevulinate photodynamic diagnosis for multifocal recurrent nonmuscle invasive bladder cancer. J Endourol 23 (2009) 983-988
48. Karl A., Tritschler S., Stanislaus P., et al. Positive urine cytology but negative white-light cystoscopy: an indication for fluorescence cystoscopy?. BJU Int 103 (2009) 484-487
49. Wilby D., Thomas K., Ray E., Chappell B., and O'Brien T. Bladder cancer: new TUR techniques. World J Urol 27 (2009) 309-312